As one of the world’s foremost developers of allogeneic adult stem cells for research and clinical trials, Stemedica Cell Technologies, Inc., of San Diego, California, partners with major medical and academic centers to support preclinical and clinical studies. The privately held biopharmaceutical company produces high-quality stem cells derived from adult bone marrow, brain tissue, and retinal epithelium. Stemedica processes all three types of stem cells in a low-oxygen environment in order to encourage their ischemic-tolerant properties.
Stemedica manufacturers allogeneic adult stem cells for four specific areas of medical research: neurology, cardiology, dermatology, and ophthalmology. For neurological medicine, these products support research into spinal cord injuries, Alzheimer’s and traumatic brain injury (''TBI''). In the field of cardiology, Stemedica cells are used to develop treatments for cardiomyopathy, chronic heart failure and myocardial infarction. The company’s stem cells also serve as critical elements of studies of burns and scars and research into adult blindness caused by macular degeneration and diabetic retinopathy. Stemedica recently received a U.S. patent for a stem-cell-based treatment of diabetic retinopathy and other degenerative eye diseases. The treatment method uses Stemedica’s mesenchymal (bone marrow-derived) stem cells to restore the endothelial lining of capillary blood vessels in the retinas of patients with diabetic retinopathy to preven
Phone
(858) 658-0912
Address
5375 Mira Sorrento Place Suite 100 San Diego, California 92121